Clinical Trial Update: Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Peg-Intron (pegylated interferon alfa-2b) to prevent disease progression in patients with chronic hepatitis C and cirrhosis; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C, Cirrhosis | Phase 3 | Status: COMPLETED | Results posted: 2009-06-11